Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
The study was prematurely discontinued due to lack confidence in the Stathmin assay as a patient selection criteria and subsequent lack of confidence in the efficacy signal that was observed. The decision to terminate the study was made on January 23, 2014. It should be noted that safety concerns have not been seen in this study and have not factored into this decision.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Recurrent endometrial carcinoma
Disease progression following one or two lines of prior treatment with platinum containing chemotherapy
Tumor tissue available at time of screening for PI3K analysis
Adequate performance status
Adequate glucose control, bone marrow, kidney, liver, and heart function
You may not be if
More than 2 prior cytotoxic chemo regimens for endometrial carcinoma
Prior therapy with an agent known to be a PI3K, and or mTOR and or AKT inhibitor
Active brain metastases
Clareo Health | A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
